Related Experiment Videos
Post-polycythemia myeloid metaplasia: experience with a large cohort of patients
M L Randi1, E Barbone, F Fabris
1Institute of Medical Semeiotics, IVth Chair of Internal Medicine, University of Padua Medical School, Italy.
Abstract:
The common origin of myeloproliferative disorders can explain the possible evolution of polycythemia vera to post-polycythemia myeloid metaplasia (PPMM). Such a possible event is usually considered linked to the use of myelosuppressive agents in particular 32P. Occasionally, myelofibrosis following essential thrombocythemia has also been described. We report here 19 cases of post-polycythemia myeloid metaplasia out of 214 polycythemia vera patients (8.8%). The majority of these patients received 32P therapy. However, busulfan also seems to have some role in the modification of polycythemia vera. In particular, the association of more than one myelosuppressive agent may favour the evolution of PPMM.
Insights
Polycythemia vera can evolve into post-polycythemia myeloid metaplasia (PPMM), often linked to myelosuppressive therapies like 32P. Combined treatments may increase this risk.
Area of Science:
- Hematology
- Oncology
Background:
- Myeloproliferative disorders share a common origin, suggesting potential disease evolution pathways.
- Polycythemia vera (PV) is a myeloproliferative neoplasm that can potentially transform into other myeloid disorders.
- Post-polycythemia myeloid metaplasia (PPMM) is a recognized, albeit less common, evolution of PV.
Purpose of the Study:
- To investigate the incidence and potential risk factors for the evolution of polycythemia vera to post-polycythemia myeloid metaplasia.
- To evaluate the role of myelosuppressive therapies in this transformation.
Main Methods:
- Retrospective analysis of 214 patients diagnosed with polycythemia vera.
- Identification of patients who developed post-polycythemia myeloid metaplasia.
- Review of treatment histories, focusing on myelosuppressive agents such as 32P and busulfan.
Main Results:
- Nineteen cases (8.8%) of PPMM were identified among 214 PV patients.
- The majority of patients who developed PPMM had received 32P therapy.
- Busulfan therapy was also implicated, and the combination of multiple myelosuppressive agents appeared to increase the risk of PPMM.
Conclusions:
- The evolution of polycythemia vera to PPMM is a significant concern, occurring in approximately 8.8% of cases in this cohort.
- Myelosuppressive agents, particularly 32P and busulfan, are associated with this transformation.
- Concomitant use of multiple myelosuppressive agents may further elevate the risk of developing PPMM from PV.